Androgen receptor-mTOR crosstalk is regulated by testosterone availability: Implication for prostate cancer cell survival

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 3895-3901

  Wu, Yue ^a   Chhipa, Rishi Raj ^a   Cheng, Jinrong ^a   Zhang, Haitao ^b   Mohler, James L ^a,c,d   Ip, Clement ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen deprivation therapy; TSC1; TSC2

Indexed keywords

ANDROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; TESTOSTERONE;

ARTICLE; BIOAVAILABILITY; CANCER CELL; CELL COMMUNICATION; CELL DEATH; CELL SURVIVAL; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANILIDES; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIROLIMUS; TESTOSTERONE; TOR SERINE-THREONINE KINASES; TOSYL COMPOUNDS; TUMOR SUPPRESSOR PROTEINS;

EID: 78650232211     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Buttyan R, Ghafar MA and Shabsigh A: The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 10: 415-420, 2000.
2. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
3. Averous J and Proud CG: When translation meets transformation: the mTOR story. Oncogene 25: 6423-6435, 2006.
4. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
5. Xu Y, Chen S-Y, Ross KN and Balk SP: Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 66: 7783-7792, 2006.
6. Cinar B, De Benedetti A and Freeman MR: Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin. Cancer Res 65: 2547-2553, 2005.
7. Wang Y, Mikhailova M, Bose S, Pan C-X, deVere White RW and Ghosh PM: Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27: 7106-7117, 2008.
8. Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R and von Schoultz B: A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. The Prostate 14: 177-182, 1989.
9. Wu Y, Fabritius M and Ip C: Chemotherapeutic sensitization by endoplasmic reticulum stress. Cancer Biol Ther 8: 146-152, 2009.
10. Cockshott ID: Bicalutamide: Clinical pharmacokinetics and metabolism. Clin Pharmacokinet 43: 855-878, 2004.
11. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
12. Mak BC and Yeung RS: The tuberous sclerosis complex genes in tumor development. Cancer Invest 22: 588-603, 2004.
13. Kuo H-P, Lee D-F, Chen C-T, Liu M, Chou C-K, Lee H-K, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang J-Y, Yen C-J, Huang T-H, Tan M, Xing G, Zhao Y, Lin C-H, Tsai S-F, Fidler IJ and Hung M-C: ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Science Signal 3: DOI: 10.1126/scisignal.2000590, 2010.
14. Hu J, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ and Xiong Y: WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev 22: 866-871, 2008.
15. Dan HC, Sun M, Yang L, Feldman RI, Sui X-M, Ou CC, Neilist M, Yeung RS, Halley DJJ, Nicosia SV, Pledger WJ and Cheng JQ: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277: 35364-35370, 2002.
16. Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, Forti G and Baldi E: Prostate cancer: A model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids 73: 1030-1037, 2008.
17. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA and Marcelli M: Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156-7168, 2004.
18. Chen CD, Welsbie DS, Tran C, Baek S-H, Chen R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nature Med 10: 33-39, 2004.
19. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA and Visakorpi T: Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149, 2009.